| pubmed-article:3050471 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:3050471 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:3050471 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:3050471 | lifeskim:mentions | umls-concept:C0231241 | lld:lifeskim |
| pubmed-article:3050471 | lifeskim:mentions | umls-concept:C0065502 | lld:lifeskim |
| pubmed-article:3050471 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:3050471 | pubmed:dateCreated | 1988-11-15 | lld:pubmed |
| pubmed-article:3050471 | pubmed:abstractText | In an open-label study, we substituted conventional levodopa plus benserazide: 100/25 (Madopar) with a controlled-release form (HBS) in 18 fluctuating parkinsonian patients for 24 months. Significantly positive results were obtained in both peak-dose and diphasic dyskinesias up to 12 months of treatment; morning akinesias were also improved up to 6 months. A general trend of deterioration, compared to the first 3-6 months of HBS treatment, was observed in "off" fluctuations after 1 year: akinesias due to a delayed response worsened after 1 year of treatment also when compared with the conventional treatment. Positive results were obtained with new HBS on standard Madopar-related psychiatric disorders. | lld:pubmed |
| pubmed-article:3050471 | pubmed:language | eng | lld:pubmed |
| pubmed-article:3050471 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3050471 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:3050471 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3050471 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3050471 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3050471 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3050471 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3050471 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3050471 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3050471 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:3050471 | pubmed:issn | 0885-3185 | lld:pubmed |
| pubmed-article:3050471 | pubmed:author | pubmed-author:ScarlatoGG | lld:pubmed |
| pubmed-article:3050471 | pubmed:author | pubmed-author:PezzoliGG | lld:pubmed |
| pubmed-article:3050471 | pubmed:author | pubmed-author:ZecchinelliAA | lld:pubmed |
| pubmed-article:3050471 | pubmed:author | pubmed-author:FerranteCC | lld:pubmed |
| pubmed-article:3050471 | pubmed:author | pubmed-author:CossuttaEE | lld:pubmed |
| pubmed-article:3050471 | pubmed:author | pubmed-author:TeseiSS | lld:pubmed |
| pubmed-article:3050471 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:3050471 | pubmed:volume | 3 | lld:pubmed |
| pubmed-article:3050471 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:3050471 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:3050471 | pubmed:pagination | 37-45 | lld:pubmed |
| pubmed-article:3050471 | pubmed:dateRevised | 2009-12-23 | lld:pubmed |
| pubmed-article:3050471 | pubmed:meshHeading | pubmed-meshheading:3050471-... | lld:pubmed |
| pubmed-article:3050471 | pubmed:meshHeading | pubmed-meshheading:3050471-... | lld:pubmed |
| pubmed-article:3050471 | pubmed:meshHeading | pubmed-meshheading:3050471-... | lld:pubmed |
| pubmed-article:3050471 | pubmed:meshHeading | pubmed-meshheading:3050471-... | lld:pubmed |
| pubmed-article:3050471 | pubmed:meshHeading | pubmed-meshheading:3050471-... | lld:pubmed |
| pubmed-article:3050471 | pubmed:meshHeading | pubmed-meshheading:3050471-... | lld:pubmed |
| pubmed-article:3050471 | pubmed:meshHeading | pubmed-meshheading:3050471-... | lld:pubmed |
| pubmed-article:3050471 | pubmed:meshHeading | pubmed-meshheading:3050471-... | lld:pubmed |
| pubmed-article:3050471 | pubmed:meshHeading | pubmed-meshheading:3050471-... | lld:pubmed |
| pubmed-article:3050471 | pubmed:meshHeading | pubmed-meshheading:3050471-... | lld:pubmed |
| pubmed-article:3050471 | pubmed:meshHeading | pubmed-meshheading:3050471-... | lld:pubmed |
| pubmed-article:3050471 | pubmed:meshHeading | pubmed-meshheading:3050471-... | lld:pubmed |
| pubmed-article:3050471 | pubmed:meshHeading | pubmed-meshheading:3050471-... | lld:pubmed |
| pubmed-article:3050471 | pubmed:meshHeading | pubmed-meshheading:3050471-... | lld:pubmed |
| pubmed-article:3050471 | pubmed:meshHeading | pubmed-meshheading:3050471-... | lld:pubmed |
| pubmed-article:3050471 | pubmed:year | 1988 | lld:pubmed |
| pubmed-article:3050471 | pubmed:articleTitle | Madopar HBS in fluctuating parkinsonian patients: two-year treatment. | lld:pubmed |
| pubmed-article:3050471 | pubmed:affiliation | Istituto di Clinica Neurologica, Università di Milano, Italy. | lld:pubmed |
| pubmed-article:3050471 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:3050471 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3050471 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3050471 | lld:pubmed |
